On November 20, 2023, Mr. Lin Changqing, Chairman and president of Beijing Hotgen Biotech Co., Ltd., Professor Du Jie, President of Beijing Antai Institute of Cardiovascular Medicine, and Professor Sun Zhiwei, General Manager of Beijing Sungen Biomedical Technology Co., Ltd., jointly launched the "Joint Laboratory of Cardiovascular Disease Biological Innovation Drug Research and Development Center". This is a landmark launch ceremony, marking that Hotgen Biotech and its affiliates, with the support of Antai Institute of Cardiovascular Medicine, have entered a stage of rapid development in cardiovascular diseases from diagnosis to treatment.
Report on Cardiovascular Health and Diseases in China 2022 has the following data on the prevalence trend of cardiovascular diseases: The prevalence of Cardiovascular Disease (CVD) is on the rise in China. The estimated number of CVD patients is 330 million, including 13 million stroke, 11.39 million coronary heart disease, 8.9 million heart failure, 5 million pulmonary heart disease, 4.87 million atrial fibrillation, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million peripheral artery disease, and 245 million hypertension. In 2020, ischemic heart disease, hemorrhagic stroke, and ischemic stroke were three leading causes of CVD death in China.
In 2022, the National Development and Reform Commission issued the 14th Five-Year Plan for Bioeconomy Development, which is China's first five-year plan for bioeconomy. The plan lists the "development of biopharmaceuticals for people's life and health" as one of four key development areas of the bioeconomy, which provides new opportunities for the innovation of China's biopharmaceutical industry. The Outline of the "Healthy China 2030" plan also clearly proposes to promote the development of the pharmaceutical industry, strengthen pharmaceutical technology innovation, and develop biological drugs. In China, the industry chain of biotechnology drugs is emerging, represented by antibody drugs, nucleic acid drugs, new vaccines, and live bacteria drugs.
Mr. Lin Changqing, Chairman and president of Beijing Hotgen Biotech Co., Ltd., said at the ceremony: Hotgen Biotech is a high-tech enterprise with the mission of "developing biotechnology for the benefit of human health". We always focus on scientific and technological innovation, constantly increase R&D investment, actively develop new products, and continue to explore new diagnostic technologies and diagnostic markers. At the same time, we explore new business areas, and gradually increase investment in antibody drugs, nucleic acid drugs, live bacteria drugs and other therapeutic fields, to achieve the company's two goals of in vitro diagnosis and biopharmaceuticals. The development of bioinnovative drugs in China is still in an initial stage. The production capacity of domestic bioinnovative drugs only accounts for 2% of that in the United States, and there is a lot of work to do. From clinical needs, problems such as the clustering of targets and indications still exist. Therefore, focusing on cardiovascular diseases with high mortality, researching new targets and new mechanisms of action, and making first-in-class innovative biological drugs are our important goals. This time, we will cooperate with Professor Du Jie to build the "Joint Laboratory of Cardiovascular Disease Biological Innovation Drug Research and Development Center", which will focus on development of innovative drugs such as antibodies and nucleic acid drugs in the cardiovascular field, to achieve advantages and open up new directions.
Professor Du Jie, president of Beijing Antai Institute of Cardiovascular Medicine, said that the institute was exploring the transformation of innovative research results, committed to exchanges and cooperation in the field of science and medicine, and carried out basic and clinical medical research on cardiovascular diseases. By integrating the resources of the Beijing-Tianjin-Hebei Cardiovascular Precision Medicine Alliance and the Laboratory of Major Cardiovascular Diseases of the Ministry of Education, we are committed to build an innovative platform for the prevention and treatment of cardiovascular diseases. At present, the institute has carried out the research of FIC drugs, rapid diagnosis, risk stratification and prognosis rapid diagnosis system for the treatment of cardiac patients. Related products are optimized and under pilot tests. The joint laboratory will facilitate research of new biomarkers, innovative emergency drugs, and technologies for the diagnosis and treatment of cardiovascular diseases.
The operation of the "Joint Laboratory of Cardiovascular Disease Biological Innovation Drug Research and Development Center" integrates the advantages of Beijing Hotgen Biotech, its affiliated companies and Beijing Antai Institute of Cardiovascular Medicine, with resource sharing and complementary advantages. We look forward to more research results from this joint laboratory in the future to bring more benefits to patients with cardiovascular diseases around the world.
Updated: Jul 24, 2024
